Drug susceptibility analysis method, analysis system and application for non-diagnostic and therapeutic purposes of tumor transplantation model

Abstract

The invention discloses a drug sensitivity analysis method suitable for non-diagnostic and therapeutic purposes of tumor transplantation models, comprising the steps of: selecting a PDX drug sensitivity test response mode; data quality control; and statistically analyzing whether there is a significant tumor volume between each experimental arm difference; compare the tumor volume growth curves between each experimental arm and the blank control group; determine the drug sensitivity level of each experimental mouse, and calculate the drug efficacy evaluation index disease control rate of each experimental arm; calculate each The tumor inhibition rate of the experimental arm; the drug efficacy of different experimental arms was sorted according to the disease control rate and tumor inhibition rate. The method of the invention includes the selection of experimental modes, data quality control, data analysis and result display, and provides a multi-level and complete solution for PDX drug sensitivity analysis.

Description

technical field [0001] The invention relates to the fields of pharmacy and biostatistics, in particular to a drug sensitivity analysis method, an analysis system and an application thereof suitable for tumor transplantation models. Background technique [0002] Tumor xenograft model (Patient-derived xenograft, PDX) is a tumor model constructed by transplanting patient's tumor tissue into immunodeficient mice. PDX can maintain the original molecular, genetic, and tissue characteristics of tumor patients, as well as intra-tumor and inter-tumor heterogeneity (Reference 1). Existing studies have confirmed that the response of tumor patients to drugs is highly consistent with the response of corresponding PDX to drugs (References 2-4), which indicates that PDX has a wide range of applications in preclinical drug testing and personalized drug screening. Value. [0003] However, in order to ensure that PDX can play its role reliably, supporting drug susceptibility analysis tools ...

AI Technical Summary

Problems solved by technology

Compared with tumor cell line models, PDX models have obvious differences in biological characteristics (such as cell composition, genetic heterogeneity) and experimental techniques (such as measurement indicators), and the drug sensitivity analysis methods of tumor cell lines cannot be directly applied Based on PDX model (Document 4)

Compared with clinical trials, the differences in the indicators for evaluating drug efficacy and trial design (sample size, whether to consider tumor duplication, whether to consider intratumoral heterogeneity) and other aspects also hinder the application of clinical trial drug sensitivity analysis methods in PDX. (Document 5)

Images